{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/post-traumatic-stress-disorder/prescribing-information/venlafaxine/","result":{"pageContext":{"chapter":{"id":"21362ceb-fea6-5f5e-a2fe-3a66b96f23bb","slug":"venlafaxine","fullItemName":"Venlafaxine","depth":2,"htmlHeader":"<!-- begin field 519df406-e36e-47ef-b546-a9e800d4c6c2 --><h2>Venlafaxine</h2><!-- end field 519df406-e36e-47ef-b546-a9e800d4c6c2 -->","summary":"","htmlStringContent":"<!-- begin item 8eb8ae1f-decb-4966-b9e4-a9e800d4c691 --><!-- end item 8eb8ae1f-decb-4966-b9e4-a9e800d4c691 -->","topic":{"id":"533afaeb-861a-55f6-ae85-a0876ad3c4ab","topicId":"4676b2a0-1d7e-49c9-a79f-d2d558307370","topicName":"Post-traumatic stress disorder","slug":"post-traumatic-stress-disorder","lastRevised":"Last revised in October 2020","chapters":[{"id":"6114e299-9845-5fc0-92b9-5c972e9c90f1","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"52893b93-e424-59ff-84a1-7dd9d9c8621a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"4be53e3f-4d5e-556c-a6ed-aeebfd10913f","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"5d1733e3-23d7-5fe8-b3cd-8444b4097187","slug":"changes","fullItemName":"Changes"},{"id":"3b6b3dc7-0b46-5df1-a1c8-9e7d1cfc1bf5","slug":"update","fullItemName":"Update"}]},{"id":"924b02ab-fe04-5ca6-bfe4-efb3fa6b1e5c","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"ddf247aa-bfb1-5234-9e83-9df355d28fbb","slug":"goals","fullItemName":"Goals"},{"id":"afdc351f-4815-5456-9d22-1e17d70923b9","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"fa4ae569-9575-57de-8a77-f97e6acf134e","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"441dbc06-ae69-5d87-b878-08acf874b06d","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"380572c6-6c66-5ecd-bb4a-907f070efec7","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"6e104865-1bd8-5bbc-a881-5acad7b59200","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"f7a4b151-95d9-5da2-8bbb-3515fae24bcc","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e8e51f81-8392-5390-8f30-d6a8e5f38014","slug":"definition","fullItemName":"Definition"},{"id":"0826975d-685e-520a-9295-f3528d50f411","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"f35f4ff7-1d48-5dc1-acb1-c6b04aee33a8","slug":"prevalence","fullItemName":"Prevalence"},{"id":"3c03bd4a-5a08-5bb7-8f67-78a04deaff9a","slug":"prognosis","fullItemName":"Prognosis"},{"id":"406fb31f-fa1e-5214-b69e-e347e6875458","slug":"complications","fullItemName":"Complications"}]},{"id":"331796fb-0b83-5add-8e42-d0b72a892df8","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"2ee24530-3791-5949-93f2-a856c919f68d","slug":"diagnosis","fullItemName":"Diagnosis"}]},{"id":"fae5c916-6c3e-5d0f-8700-e051eb95a992","fullItemName":"Management","slug":"management","subChapters":[{"id":"3a0b4bd2-81cd-5c2c-bb02-7c2734e8ebed","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"2022c3bf-f856-5c11-b2fa-f455afe14e13","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"8c49cc16-aec3-5fe6-98f3-6facc85e65a4","slug":"ssris","fullItemName":"SSRIs"},{"id":"21362ceb-fea6-5f5e-a2fe-3a66b96f23bb","slug":"venlafaxine","fullItemName":"Venlafaxine"}]},{"id":"ace3b310-05bb-5555-9074-19f51f5bcc46","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"94089c18-8f8a-5c71-b9fa-98bab016d27c","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"fb1c0b33-ff77-5312-9d64-544591ee5a16","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"ab823271-5683-5fa8-9990-359b8361a067","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"4977229b-c104-593f-9254-5b46fd4cef6b","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"aa78f3e8-f7e9-5ec9-98a7-ab3a2ded7822","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"40d90bf9-fb45-51a8-8085-ff7f6501f6e7","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"ad5c3e2a-1074-579a-82d5-e2675befc03f","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"2022c3bf-f856-5c11-b2fa-f455afe14e13","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"6fb14c0f-7827-50b0-9fbd-85bf01bc2c4d","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 9c43b0ef-30ee-4272-b352-a9e800d4d643 --><h3>Contraindications and cautions</h3><!-- end field 9c43b0ef-30ee-4272-b352-a9e800d4d643 -->","summary":"","htmlStringContent":"<!-- begin item a249df4c-9fe8-460b-990e-a9e800d4d5f9 --><!-- begin field 90826f50-d66e-4f06-8e58-a9e800d4d643 --><ul><li><strong>Do not prescribe venlafaxine to people:</strong><ul><li>With uncontrolled hypertension.</li><li>Taking a monoamine oxidase inhibitor (MAOI), or who have recently discontinued an MAOI.</li><li>With conditions associated with high risk of cardiac arrhythmia.</li></ul></li><li><strong>Prescribe venlafaxine with caution to people with:</strong><ul><li>Bleeding disorders.<ul><li>Older people or people taking drugs that can damage the gastrointestinal mucosa or interfere with clotting (for example, NSAIDS or aspirin) may also be at risk. Consider prescribing a gastroprotective drug in these circumstances.</li></ul></li><li>Cardiac disease.</li><li>Diabetes.</li><li>A recent history of myocardial infarction.</li><li>A history of mania.</li><li>Narrow-angle glaucoma or increased intraocular pressure.</li><li>History of seizures.</li><li>Hypertension.<ul><li>For venlafaxine, all people should therefore be screened for high blood pressure and preexisting hypertension should be controlled before initiation of treatment. Blood pressure should be reviewed periodically, after initiation of treatment, and after dose increases.</li><li>With use of venlafaxine, caution should be exercised in people whose underlying conditions might be compromised by increases in blood pressure, such as those with impaired cardiac function.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/post-traumatic-stress-disorder/references/\">ABPI, 2017e</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/post-traumatic-stress-disorder/references/\">BNF 76, 2018</a>]</p><!-- end field 90826f50-d66e-4f06-8e58-a9e800d4d643 --><!-- end item a249df4c-9fe8-460b-990e-a9e800d4d5f9 -->","subChapters":[]},{"id":"74273e00-cb7f-5880-bd2b-7a14400d5661","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 98d15106-d5a4-4f1f-a7db-a9e800d4e16e --><h3>Adverse effects</h3><!-- end field 98d15106-d5a4-4f1f-a7db-a9e800d4e16e -->","summary":"","htmlStringContent":"<!-- begin item 3199ac87-a58a-4b7f-ac5f-a9e800d4e135 --><!-- begin field 4604f237-0792-4f16-a812-a9e800d4e16e --><ul><li><strong>The most common adverse effects of venlfaxine include nausea, insomnia, dry mouth, somnolence, dizziness, constipation, sweating, nervousness, and asthenia. </strong></li><li><strong>Other adverse effects </strong><strong>include:</strong><ul><li><strong>Drowsiness </strong>— may impair performance of skilled tasks such as driving and operating machinery.<ul><li>Advise the person that it is illegal in England and Wales to drive while taking a prescribed drug if it impairs driving [<a class=\"bibliography-reference internal-reference\" href=\"/topics/post-traumatic-stress-disorder/references/\">DVLA, 2015</a>].</li></ul></li><li><strong>Hypertension.</strong> <ul><li>Venlafaxine is commonly associated with dose-related increases in blood pressure. Severely elevated blood pressure requiring immediate treatment has been reported in postmarketing experience. </li></ul></li><li><strong>Sexual dysfunction.</strong></li><li><strong>Increased risk of bleeding,</strong> especially in older people or people taking other drugs that can damage the gastrointestinal mucosa or interfere with clotting (for example nonsteroidal anti-inflammatory drugs [NSAIDs]).</li><li><strong>Hyponatraemia </strong>— risk factors for developing hyponatraemia include a history of hyponatraemia, extreme old age (greater than 80 years of age), female sex, low body weight, diuretics, diabetes mellitus, hypertension, reduced renal function, volume depletion, and chronic obstructive pulmonary disease.<ul><li>Monitor the person for signs and symptoms of hyponatraemia (such as dizziness, lethargy, nausea, confusion, cramps, and seizures).</li></ul></li><li><strong>Increased suicide risk</strong> — this is most likely in younger people (less than 30 years of age) when starting an SNRI.<ul><li>Monitor people carefully during the first few weeks of SNRI treatment; in particular, be alert for signs of suicidal ideation, akathisia, and increased anxiety and agitation. </li></ul></li><li><strong>Discontinuation symptoms</strong> (such as dizziness, sensory disturbances [including paraesthesia], sleep disturbances [including insomnia and intense dreams], agitation or anxiety, nausea and/or vomiting, tremor, and headache).<ul><li>The risk of discontinuation symptoms may be dependent on several factors including the duration and dose of therapy and the rate of dose reduction. </li><li>Generally these symptoms are mild to moderate; however, in some people they may be severe.</li><li>They usually occur within the first few days of discontinuing treatment.</li><li>Generally these symptoms are self-limiting and usually resolve within 2 weeks, though in some individuals they may be prolonged (2 – 3 months or more).</li><li>It is therefore advised that an SNRI should be gradually tapered over a period of several weeks or months, according to the person's needs.</li></ul></li><li><strong>Altered glycaemic control in people with diabetes mellitus.</strong> Monitor diabetic control in people taking venlafaxine modified-release as the doses of insulin or oral anti-diabetic drugs may need to be altered.</li><li><strong>Cardiac adverse effects:</strong><ul><li><strong>Fatal cardiac arrhythmias</strong> have been reported, especially in overdose. The balance of risks and benefits should therefore be considered before prescribing venlafaxine to people at high risk of serious cardiac arrhythmia.</li><li><strong>Takotsubo or stress cardiomyopathy.</strong> Venlafaxine has also been associated with takotsubo or stress cardiomyopathy.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/post-traumatic-stress-disorder/references/\">ABPI, 2017e</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/post-traumatic-stress-disorder/references/\">BNF 76, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/post-traumatic-stress-disorder/references/\">ABPI, 2020b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/post-traumatic-stress-disorder/references/\">ABPI, 2020c</a>]</p><!-- end field 4604f237-0792-4f16-a812-a9e800d4e16e --><!-- end item 3199ac87-a58a-4b7f-ac5f-a9e800d4e135 -->","subChapters":[]},{"id":"5c9917ef-d54d-53f4-a19c-5b9963bfdb22","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field c7a398eb-dfa8-41e6-bc04-a9e800d4ef2c --><h3>Drug interactions</h3><!-- end field c7a398eb-dfa8-41e6-bc04-a9e800d4ef2c -->","summary":"","htmlStringContent":"<!-- begin item 193afa63-90bf-49f0-83d4-a9e800d4eee9 --><!-- begin field b4590436-4d4a-45ad-894c-a9e800d4ef2c --><ul><li><strong>Key drug interactions with SNRIs as a class include:</strong><ul><li>MAOIs — CNS effects of SSRIs increased by MAOIs (risk of serious toxicity).</li><li>5HT1- receptor antagonists, dapoxetine, SSRIs, St John's Wort, tramadol — risk of increased serotonergic effects.<ul><li>The manufacturer of dapoxetine advises SNRIs should not be started until 1 week after stopping dapoxetine, and to avoid dapoxetine for 2 weeks after stopping SNRIs.</li></ul></li><li>Aspirin and NSAIDs — increased risk of bleeding.</li><li>Warfarin — increases in INR values have been reported when SNRIs were co-administered with warfarin.<ul><li>Consider frequent monitoring of the INR. </li></ul></li></ul></li><li><strong>In addition, for venlafaxine:</strong><ul><li>Amiodarone, erythromycin, moxifloxacin, sotalol — avoid concomitant use due to risk of ventricular arrhythmias. <ul><li><strong>Note:</strong> Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment has been stopped.</li></ul></li><li>Bupropion — plasma concentration of venlafaxine increased by bupropion.</li><li>Entacapone — caution with venlafaxine advised by the manufacturer of entacapone.</li><li>Haloperidol — venlafaxine increases plasma concentration of haloperidol.</li><li>Lithium, mirtazapine — possible increased serotonergic effects.</li><li>Selegiline — increased risk of hypertension and CNS excitation. Selegiline should not be started until 1 week after stopping venlafaxine, avoid venlafaxine for 2 weeks after stopping selegiline.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/post-traumatic-stress-disorder/references/\">ABPI, 2017e</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/post-traumatic-stress-disorder/references/\">BNF 76, 2018</a>]</p><!-- end field b4590436-4d4a-45ad-894c-a9e800d4ef2c --><!-- end item 193afa63-90bf-49f0-83d4-a9e800d4eee9 -->","subChapters":[]},{"id":"19443558-2df3-55c0-8cb2-d52f76d24186","slug":"dosage","fullItemName":"Dosage","depth":3,"htmlHeader":"<!-- begin field acacfde7-50f1-4ef9-b871-a9e800d4fdf3 --><h3>Dosage</h3><!-- end field acacfde7-50f1-4ef9-b871-a9e800d4fdf3 -->","summary":"","htmlStringContent":"<!-- begin item 397e8037-a043-4f58-8ecd-a9e800d4fdc0 --><!-- begin field 402d74c6-cc8f-461c-9d6f-a9e800d4fdf3 --><p><strong>Note: venlafaxine is not licensed for the treatment of post-traumatic stress disorder and use for this indication, therefore, constitutes an off-licence use.</strong></p><ul><li>Modified release products are recommended for anxiety disorders.</li><li>The recommended starting dose is 75 mg once daily, increased if necessary up to 225 mg once daily. Dose to be increased at intervals of at least 2 weeks; maximum 225 mg per day.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/post-traumatic-stress-disorder/references/\">ABPI, 2017e</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/post-traumatic-stress-disorder/references/\">BNF 76, 2018</a>]</p><!-- end field 402d74c6-cc8f-461c-9d6f-a9e800d4fdf3 --><!-- end item 397e8037-a043-4f58-8ecd-a9e800d4fdc0 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}